Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report

Medicina

Eraci Drehmer¹  Felix Platero²  María Benlloch³  JoseLuis Platero³  JoseEnrique de la Rubia Ortí³  MaríaMar López-Rodríguez⁴  Pablo Selvi Sabater⁵  Jesús Escribá-Alepuz⁶  Antonio Bustos⁷ 

[1] Department of Basic Sciences, Catholic University of Valencia San Vicente Mártir, 46900 Torrente, Valencia, Spain;Department of Medicine, University of Valencia, 46003 Valencia, Spain;Department of Nursing, Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain;Department of Nursing, Physiotherapy and Medicine, University of Almería, 04120 Almería, Spain;Hospital de Riotinto, 21660 Huelva, Spain;Neurophysiology Department, Sagunto University Hospital, 46520 Valencia, Spain;Physical Therapy Clinic, Antonio Bustos, 46007 Valencia, Spain;

关键词: Charcot-Marie-Tooth disease type 2;    epigallocatechin gallate;    IL-6;    motor activity;    paraoxonase 1;   

DOI  :  10.3390/medicina57020104

来源: DOAJ

【 摘 要 】

Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk test (10MWT), nine-hole peg test (9HPT) and handgrip strength measurement using a handheld Jamar dynamometer. Results: Regarding muscular and motor functions associated with higher inflammation and oxidation, improvements only observed in the woman in all analysed parameters (both biochemical and clinical associated with the metabolism and functionality) after 4 months of treatment with EGCG are noteworthy. Thus, this treatment is proposed as a good candidate to treat the disease.

【 授权许可】

Unknown